Chemotherapy-free treatment of recurrent advanced ovarian cancer: Myth or reality?

Cristiana Marques, Filipa Ferreira Da Silva, Isabel Sousa, Mónica Nave

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)
31 Downloads (Pure)

Abstract

Advanced ovarian cancer remains a leading cause of death from gynecologic malignancy. Surgery and, in most cases, platinum-based chemotherapy with or without maintenance with bevacizumab and/or poly-ADP ribose polymerase inhibitors (PARPi) represent the mainstay of treatment, but the disease typically recurs. The treatment of these patients represents a clinical challenge because sequential chemotherapy regimens are often used, with suboptimal outcomes and cumulative toxicity. Chemotherapy-free regimens, based on combinations of PARPi, vascular endothelial growth factor receptor inhibitors, anti-programmed cell death protein-1/programmed death-ligand 1, and anti-cytotoxic T-lymphocyte-associated protein-4 antibodies, among others, represent a valid option, with manageable toxicity profile and ease of administration. This review addresses this new strategy in the management of recurrent ovarian cancer and discusses its feasibility in the treatment landscape of the disease.

Original languageEnglish
Article numbere22003719
Pages (from-to)607 - 618
JournalInternational Journal Of Gynecological Cancer
Volume33
Issue number4
Early online date2022
DOIs
Publication statusPublished - Apr 2023

Keywords

  • gynecology
  • medical oncology
  • ovarian cancer
  • ovarian neoplasms
  • ovary

Fingerprint

Dive into the research topics of 'Chemotherapy-free treatment of recurrent advanced ovarian cancer: Myth or reality?'. Together they form a unique fingerprint.

Cite this